Immune Checkpoint Inhibitors in the Treatment of Renal Cell Carcinoma

Mamta Parikh; Poornima Bajwa

doi:10.1016/j.semnephrol.2019.12.009

Immune Checkpoint Inhibitors in the Treatment of Renal Cell Carcinoma

Mamta Parikh, Poornima Bajwa

Hematology and Oncology

Research output: Contribution to journal › Review article › peer-review

1 Scopus citations

Abstract

Summary: Immune checkpoint inhibitors have quickly become a critical component to the management of advanced renal cell carcinoma. These therapies have been approved for patients who are treatment-naive and who have progressed on antiangiogenesis agents. Combinations of immune checkpoint inhibitors with antiangiogenesis agents show significant response rates and prolong survival. Adverse events associated with the use of checkpoint inhibition present unique challenges in the management of patients, and careful considerations are needed when checkpoint inhibitors are combined with antiangiogenesis agents. Nevertheless, the improvement in overall survival associated with these agents indicates that they will remain a vital component of kidney cancer treatment.

Original language	English (US)
Journal	Seminars in Nephrology
DOIs	https://doi.org/10.1016/j.semnephrol.2019.12.009
State	Accepted/In press - Jan 1 2020

Keywords

checkpoint inhibition
immune-related adverse events
Immunotherapy
kidney cancer
renal cell carcinoma

ASJC Scopus subject areas

Nephrology

Access to Document

10.1016/j.semnephrol.2019.12.009

Fingerprint Dive into the research topics of 'Immune Checkpoint Inhibitors in the Treatment of Renal Cell Carcinoma'. Together they form a unique fingerprint.

Cite this

@article{645ee4096e3f434f8ec8a9cce855f686,

title = "Immune Checkpoint Inhibitors in the Treatment of Renal Cell Carcinoma",

abstract = "Summary: Immune checkpoint inhibitors have quickly become a critical component to the management of advanced renal cell carcinoma. These therapies have been approved for patients who are treatment-naive and who have progressed on antiangiogenesis agents. Combinations of immune checkpoint inhibitors with antiangiogenesis agents show significant response rates and prolong survival. Adverse events associated with the use of checkpoint inhibition present unique challenges in the management of patients, and careful considerations are needed when checkpoint inhibitors are combined with antiangiogenesis agents. Nevertheless, the improvement in overall survival associated with these agents indicates that they will remain a vital component of kidney cancer treatment.",

keywords = "checkpoint inhibition, immune-related adverse events, Immunotherapy, kidney cancer, renal cell carcinoma",

author = "Mamta Parikh and Poornima Bajwa",

year = "2020",

month = jan,

day = "1",

doi = "10.1016/j.semnephrol.2019.12.009",

language = "English (US)",

journal = "Seminars in Nephrology",

issn = "0270-9295",

publisher = "W.B. Saunders Ltd",

}

TY - JOUR

T1 - Immune Checkpoint Inhibitors in the Treatment of Renal Cell Carcinoma

AU - Parikh, Mamta

AU - Bajwa, Poornima

PY - 2020/1/1

Y1 - 2020/1/1

N2 - Summary: Immune checkpoint inhibitors have quickly become a critical component to the management of advanced renal cell carcinoma. These therapies have been approved for patients who are treatment-naive and who have progressed on antiangiogenesis agents. Combinations of immune checkpoint inhibitors with antiangiogenesis agents show significant response rates and prolong survival. Adverse events associated with the use of checkpoint inhibition present unique challenges in the management of patients, and careful considerations are needed when checkpoint inhibitors are combined with antiangiogenesis agents. Nevertheless, the improvement in overall survival associated with these agents indicates that they will remain a vital component of kidney cancer treatment.

AB - Summary: Immune checkpoint inhibitors have quickly become a critical component to the management of advanced renal cell carcinoma. These therapies have been approved for patients who are treatment-naive and who have progressed on antiangiogenesis agents. Combinations of immune checkpoint inhibitors with antiangiogenesis agents show significant response rates and prolong survival. Adverse events associated with the use of checkpoint inhibition present unique challenges in the management of patients, and careful considerations are needed when checkpoint inhibitors are combined with antiangiogenesis agents. Nevertheless, the improvement in overall survival associated with these agents indicates that they will remain a vital component of kidney cancer treatment.

KW - checkpoint inhibition

KW - immune-related adverse events

KW - Immunotherapy

KW - kidney cancer

KW - renal cell carcinoma

UR - http://www.scopus.com/inward/record.url?scp=85078881068&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85078881068&partnerID=8YFLogxK

U2 - 10.1016/j.semnephrol.2019.12.009

DO - 10.1016/j.semnephrol.2019.12.009

M3 - Review article

C2 - 32130969

AN - SCOPUS:85078881068

JO - Seminars in Nephrology

JF - Seminars in Nephrology

SN - 0270-9295

ER -